On August 28, 2019 Oncopeptides reported Interim Report Q2 2019 (Press release, Oncopeptides, AUG 28, 2019, View Source [SID1234539091]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Financial overview April 1 – June 30, 2019
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 171.9 M (loss: 144.6)
Loss per share, before and after dilution, was SEK 3.52 (loss: 3.30)
On June 30 cash and cash equivalents amounted to SEK 626.8 M (568.2)
Significant events during the period April 1 – June 30, 2019
In April, melflufen was granted additional patent protection in the US until 2033
In April it was announced that the last patient in the OCEAN trial is estimated to be enrolled during Q1 2020
In May it was announced that Oncopeptides will apply for accelerated approval in the US
In the beginning of June, at ASCO (Free ASCO Whitepaper)’s 2019 Annual Meeting in the United States, Oncopeptides presented new data from the Phase 1/2 study called O-12-M1 with melflufen in RRMM patients
At the European Hematology Meeting, EHA (Free EHA Whitepaper) in June, Oncopeptides presented new data from the pivotal phase 2 study HORIZON with melflufen in RRMM patients. New data from the phase 1/2 combination study ANCHOR were also presented at the conference
In June, Oncopeptides resolved to make a directed share issue of SEK 727 M before issue costs (approximately USD 78 M). The share issue was completed in July
Significant events after the reporting period
In late August it was announced that Klaas Bakker was appointed as the new Chief Medical Officer for Oncopeptides. He starts his work in November
Financial overview of the group
Earnings per share before and after dilution (SEK)
[1] Earlier periods have been adjusted to reflect correction of errors, see note 8.
Conference call for investors, analysts and the media
The Interim Report Q2 2019 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Wednesday August 28, 2019 at 15:00 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.
Phone numbers for participants from:
Sweden: +46-8-505-583-59
Europe: +44-3333-009-032
USA: +1-833-823-05-90
Financial calendar
Interim Report Q3, 2019: November 19, 2019
Year-end Report 2019: February 20, 2020
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on August 28, 2019.